1. Home
  2. DFH vs PVLA Comparison

DFH vs PVLA Comparison

Compare DFH & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dream Finders Homes Inc.

DFH

Dream Finders Homes Inc.

HOLD

Current Price

$15.90

Market Cap

1.7B

ML Signal

HOLD

Logo Palvella Therapeutics Inc.

PVLA

Palvella Therapeutics Inc.

HOLD

Current Price

$139.03

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFH
PVLA
Founded
2008
2015
Country
United States
United States
Employees
N/A
29
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
DFH
PVLA
Price
$15.90
$139.03
Analyst Decision
Hold
Strong Buy
Analyst Count
2
15
Target Price
$26.00
$171.87
AVG Volume (30 Days)
568.5K
285.1K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.11
N/A
Revenue
$4,322,848,000.00
N/A
Revenue This Year
$0.81
N/A
Revenue Next Year
$7.82
$104,350.18
P/E Ratio
$133.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.20
$34.57
52 Week High
$31.10
$161.38

Technical Indicators

Market Signals
Indicator
DFH
PVLA
Relative Strength Index (RSI) 51.70 50.98
Support Level $13.71 $106.07
Resistance Level $16.46 $156.88
Average True Range (ATR) 0.79 11.22
MACD -0.14 -1.80
Stochastic Oscillator 58.39 52.02

Price Performance

Historical Comparison
DFH
PVLA

About DFH Dream Finders Homes Inc.

Dream Finders Homes Inc designs, builds and sells homes in markets throughout the United States. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the maximum of its revenue from the Midwest segment.

About PVLA Palvella Therapeutics Inc.

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Share on Social Networks: